ProCE Banner Activity

Should We Screen Patients With HIV for NAFLD/NASH?

Clinical Thought
The presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues can trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV.

Released: September 29, 2021

Expiration: September 28, 2022

No longer available for credit.

Share

Faculty

Giada Sebastiani

Giada Sebastiani, MD

Associate Professor of Medicine
McGill University Health Centre
Division of Gastroenterology and Hepatology and Division of Infectious Diseases
Clinician Scientist
Research Institute of McGill University Health Centre
Montreal, Quebec, Canada

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Theratechnologies

Faculty Disclosure

Primary Author

Giada Sebastiani, MD

Associate Professor of Medicine
McGill University Health Centre
Division of Gastroenterology and Hepatology and Division of Infectious Diseases
Clinician Scientist
Research Institute of McGill University Health Centre
Montreal, Quebec, Canada

Giada Sebastiani, MD, has disclosed that she has received funds for research support from Merck and Theratec; consulting fees from Allergan, Intercept, Gilead Sciences, Merck, Novartis, Novo Nordisk, and Pfizer; and fees for non-CME/CE services from AbbVie, Gilead Sciences, Merck, Novartis, Novo Nordisk, and Pfizer.